Cargando…

Castration-resistant prostate cancer cells are dependent on the high activity of CDK7

PURPOSE: Prostate cancer (PC) is successfully treated with anti-androgens; however, a significant proportion of patients develop resistance against this therapy. Anti-androgen-resistant disease (castration-resistant prostate cancer; CRPC) is currently incurable. Cyclin-dependent kinase 7 (CDK7) is p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pallasaho, Satu, Gondane, Aishwarya, Kuivalainen, Anni, Girmay, Samuel, Moestue, Siver, Loda, Massimo, Itkonen, Harri M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349716/ https://www.ncbi.nlm.nih.gov/pubmed/36401094 http://dx.doi.org/10.1007/s00432-022-04475-3

Ejemplares similares

O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage
por: Gondane, Aishwarya, et al.
Publicado: (2022)

O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition
por: Gondane, Aishwarya, et al.
Publicado: (2022)

Revealing the History and Mystery of RNA-Seq
por: Gondane, Aishwarya, et al.
Publicado: (2023)

Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells
por: Barkovskaya, Anna, et al.
Publicado: (2020)

O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
por: Barkovskaya, Anna, et al.
Publicado: (2019)

Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism
por: Itkonen, Harri M., et al.
Publicado: (2016)

CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation
por: Itkonen, Harri M., et al.
Publicado: (2019)

R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T
por: Kim, Jana, et al.
Publicado: (2019)

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
por: Choi, Stephen Y. C., et al.
Publicado: (2022)

Intravascular Targets for Molecular Contrast-Enhanced Ultrasound Imaging
por: Moestue, Siver A., et al.
Publicado: (2012)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Polycomb-independent activity of EZH2 in castration resistant prostate cancer
por: Xu, Kexin, et al.
Publicado: (2013)

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
por: Chen, Xi, et al.
Publicado: (2022)

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
por: Han, Wanting, et al.
Publicado: (2022)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy
por: Liao, Yuning, et al.
Publicado: (2020)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Educational inequalities in employment of Finns aged 60–68 in 2006–2018
por: Polvinen, Anu, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer
por: Søgaard, Caroline K., et al.
Publicado: (2018)

Identification of Metastasis-Associated Metabolic Profiles of Tumors by (1)H-HR-MAS-MRS()()()
por: Gorad, Saurabh S., et al.
Publicado: (2015)

Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells
por: Tunset, Hanna Maja, et al.
Publicado: (2019)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer
por: Nikhil, Kumar, et al.
Publicado: (2020)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
por: Kokontis, John M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r7l1lg07ivf3ll9r2srmtfli0b